TG Therapeutics | TGTX - Pre Tax Profit


TG Therapeutics reported $10.23M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Amgen USD 2.08B 570M Mar/2026
Ardelyx USD -37.6M 37.2M Mar/2026
Arrowhead Research USD -178.9M 41.34M Jun/2026
Bayer EUR 321M 2.67B Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
Corcept Therapeutics USD -44.72M 54.62M Mar/2026
Curis USD -24.2M 43.56M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
J&J USD 7.67B 988M Sep/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novavax USD 17.9M 220.94M Dec/2025
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
TG Therapeutics USD 10.23M 10.13M Jun/2026
Verastem USD -36.59M 3.68M Mar/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026